How much does C. S. T. Pharma Limited make?

C. S. T. Pharma Limited reported revenue of £91.3m and £1.7m profit in the year to 30 Apr 2025, according to its accounts filed at Companies House.

How many employees does C. S. T. Pharma Limited have?

C. S. T. Pharma Limited reported an average of 115 employees in the year to 30 Apr 2025.

Is C. S. T. Pharma Limited profitable?

Yes — C. S. T. Pharma Limited reported a profit of £1.7m in the year to 30 Apr 2025.

Company No. 04212740 · Incorporated 9 May 2001

C. S. T. Pharma Limited

Registered name: C. S. T. PHARMA LIMITED

Part of CST Pharma Holdings Limited group

C. S. T. Pharma Limited made £91.3m revenue and £1.7m profit in the year to 30 Apr 2025. read from filing text

C. S. T. Pharma Limited’s revenue grew 8% to £91.3m in the year to 30 Apr 2025, with £1.7m profit and 115 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in Walsall; we hold 4 years of its filed accounts.

Full P&L filedSection G · Wholesale and retail trade; repair of motor vehiclesSIC 46460Wholesale of pharmaceutical goods

Status: Active
Location: Walsall, West Midlands
Age: 25 yrs · since 2001
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The parent company is”

Latest accounts · year to 30 Apr 2025

Key figures

Capital-lightDoing more with less

Revenue

£91.3m

Growth ▲7.7%

Profit

£1.7m

Growth ▼6.2%

Profit margin

1.9%

Gross 11.3%

Employees

115

Change ▼1.7%

Profit / employee

£15.2k

Revenue/employee £794k

Profitable streak

4yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	30 Apr 2022	30 Apr 2023	30 Apr 2024	30 Apr 2025
Disclosure	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text	Full P&Lread from filing text
Profit & loss
Revenue (turnover)	£108m	£113m	£84.8m	£91.3m
Cost of sales	£96.5m	£102m	£74.2m	£81m
Gross profit	£11.5m	£11.5m	£10.6m	£10.4m
Operating profit	£4m	£3.6m	£3.3m	£3.3m
Profit before tax	£3.5m	£2.9m	£2.4m	£2.3m
Profit after tax	£2.9m	£2.4m	£1.9m	£1.7m
Profit (best available)	£2.9m	£2.4m	£1.9m	£1.7m
Staff costs	£4.6m	£4.4m	£4.4m	£4.6m
Employees (average)	149	131	117	115
Ratios
Profit margin	2.7%	2.1%	2.2%	1.9%
Gross margin	10.7%	10.2%	12.5%	11.3%
Revenue per employee	£725k	£864k	£725k	£794k
Profit per employee	£19.7k	£18.4k	£15.9k	£15.2k
Growth (year on year)
Revenue growth	—	▲4.8%	▼25.1%	▲7.7%
Profit growth	—	▼18%	▼22.6%	▼6.2%
Headcount growth	—	▼12.1%	▼10.7%	▼1.7%
Balance sheet — indirect signals, not revenue
Cash at bank	£362k	£138k	£288k	£20.7k
Net assets	£9.9m	£12.1m	£13.8m	£15.3m
Fixed assets	£1.5m	£1.7m	£2.3m	£2.3m
Current assets	£28.6m	£28.8m	£31m	£41.9m
Debtors	£10.1m	£12.1m	£10.9m	£15.8m
Deferred income	£425k	£275k	£301k	£304k
Source	FullAccounts · bulk data Jan 2024	FullAccounts · bulk data Jan 2024	FullAccounts · bulk data Dec 2024	FullAccounts · bulk data Dec 2025

Derived from the latest filing

How the business works

Profit margin: 1.9%; Profit ÷ revenue.
Gross margin: 11.3%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £794k; Revenue ÷ average employees.
Profit per employee: £15.2k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 2.5%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 0.3%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 17.3%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲11%; Now £15.3m
Cash at bank: ▼93%; Now £20.7k
Headcount: ▼2%; Now 115
Deferred income: ▲1%; Now £304k
Fixed assets: ▲1%; Now £2.3m

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

CST Pharma Holdings Limitedultimate parent75–100%
C.S.T. Pharma Group Holdings Limited75–100%
C. S. T. Pharma Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (3)

Acer Pharma LimitedRev. — · Profit £289k
Curagenix Life Sciences LimitedFigures not disclosed
MPT Pharma LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 30 Apr 2025 (profit £1.7m), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.